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Abstract
Uterine sarcomas comprise a group of rare tumours with 
differing tumour pathobiology, natural history and response 
to clinical treatment. Diagnosis is often made following sur-
gical treatment for presumed malignant mesenchymal tu-
mours and benign tumours. Currently pre-operative diag-
nosis does not reliably distinguish between malignant mes-
enchymal tumours, Uterine Leiomyosarcoma (U-LMS) and 
benign tumours including Leiomyomas (LMA). U-LMS is the 
most common sarcoma but other subtypes include endo-
metrial stromal sarcoma (low grade and high grade), un-
differentiated uterine sarcoma and adeno sarcoma. Clinical 
trials have shown no definite survival benefit for adjuvant 
radiotherapy or chemotherapy, and have been hampered 
by the rarity and heterogeneity of these tumour types. There 
is a role of adjuvant treatment in carefully selected cases 
following multidisciplinary discussion at U-LMS reference 
centres. In patients with metastatic LMS then systemic che-
motherapy can be considered. Accordingly, it is necessary 
to analyse risk factors associated with human U-LMS, in 
order to establish a treatment method. Proteasome β-sub-
unit 9 (PSMB9)/β1i-deficient mice spontaneously develop 
U-LMS, with a disease prevalence of ~37% by 12 months
of age. We found PSMB9/β1i expression to be absent in hu-
man U-LMS, but present in human LMA. Therefore, defec-
tive PSMB9/β1i expression may be one of the risk factors 
for human U-LMS. PSMB9/β1i is a potential diagnostic-bio-
marker for human U-LMS, and may be targeted-molecule 
for a new therapeutic approach.
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Introduction
Soft tissue sarcomas arising from the uterus are a 
rare and varied group of neoplasms all of mesenchymal 
origin. They can occur at any anatomical site and exhibit 
a wide range of behaviours which largely depend on the 
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histologic subtype and associated tumour grade. The 
incidence of human Uterine Leiomyosarcoma (U-LMS) 
is around 3-7% of all uterine malignancies and is asso-
ciated with a poor prognosis when compared to endo-
metrial carcinoma [1]. Recent results from Surveillance 
Epidemiology and End Results (SEER) database analysis 
have shown a higher incidence rate for those aged 40 
years or older, compared to younger patients and twice 
the incidence in women of Afro-Caribbean descent 
compared to Caucasian women [2].
The development of gynaecologic tumours is often 
correlated with female hormone secretions; however, 
the development of human U-LMS is not substantially 
correlated with hormonal conditions, and the risk fac-
tors are not yet known. Importantly, a diagnostic-bio-
marker which distinguishes malignant human U-LMS 
from other uterine mesenchymal tumours including 
benign tumour Leiomyoma (LMA) is yet to be estab-
lished. Accordingly, it is necessary to analyze risk factors 
associated with human U-LMS, in order to establish a 
treatment method. Proteasome β-subunit 9 (PSMB9)/
β1i-deficient mice spontaneously develop U-LMS, with 
a disease prevalence of ~37% by 12 months of age. We 
found PSMB9/β1i expression to be absent in human 
U-LMS, but present in human LMA. Therefore, defective 
PSMB9/β1i expression may be one of the risk factors for 
human U-LMS. PSMB9/β1i is a potential diagnostic-bio-
marker for human U-LMS, and may be targeted-mole-
cule for a new therapeutic approach.
Takuma Hayashi (Shinshu University School of Med-
icine) discussed a novel biomarker for detecting human 
U-LMS. Patients with U-LMS typically present with vag-
inal bleeding, pain and a pelvic mass, with atypical pre-
sentations of hypercalcemia and eosinophilia also being 
reported [3-5]. There is concern that radiographic eval-
uation with combined positron emission tomography/
computed tomography, which is commonly used to aid 
assessment of patient prognosis, might not necessari-
ly be effective for diagnosis and surveillance of human 
U-LMS [6-8]. Unfortunately, radiographic imaging can-
not provide any medical information to help distinguish 
between U-LMS and other uterine mesenchymal tu-
mours including benign tumour LMA [9,10].
Importantly, diagnostic biomarkers that are able to 
distinguish between human U-LMS and other uterine 
mesenchymal tumours are not yet established. In eu-
karyotes, proteasomes are large, ATP-dependent com-
plexes located in both nucleus and cytosol. The main 
function of the proteasome is to degrade unneeded or 
damaged proteins by proteolysis, a chemical reaction 
that breaks peptide bonds. The proteasome and its sub-
units are of clinical significance, a compromised com-
plex assembly or a dysfunctional proteasome can be as-
sociated with the underlying pathophysiology of specific 
diseases. Hayashi’s research group reports that PSMB9/
β1i-deficient mice exhibit spontaneous development of 
human U-LMS, with a disease prevalence of ~37% by 12 
months of age [11]. The current focus of Hayashi’s re-
search is to probe the loss of PSMB9/β1i expression in 
human U-LMS, as well as the detectable expression of 
the protein in human LMA [12,13]. Defective expression 
of PSMB9/β1i is likely to be one of the risk factors for 
the development of human uterine neoplasms, as it is in 
the PSMB9-deficient mouse. Thus, PSMB9/β1i is useful 
as a novel diagnostic biomarker for human U-LMS, and 
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Figure 1: Differential expression of PSMB9/β1i in human normal myometrium, several mesenchymal tumour types and uterine 
LANT-like malignant tumour. Immunohistchemistry (IHC) of PSMB9/β1i in normal myometrium, usual leiomyoma, Bizarre 
leiomyoma, Smooth Muscle Tumour of Uncertain Malignant Potential (STUMP) and Uterine Leiomyosarcoma (LMS) tissues 
located in same tissue, and uterine LANT-like malignant tumour. For all samples, 5-µm sections of tissues specimens were 
stained with anti-PSMB9/β1i antibody revealed by peroxidase-conjugated anti-rabbit IgG antibody. 
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Hayashi’s research group have been trying to establish 
a novel diagnostic biomarker with PSMB9/β1i, which 
can distinguish the human U-LMS from other human 
uterine mesenchymal tumours including LMA under the 
SIGMA-Aldrich Collaboration Laboratory Project.
The Immunohistochemistry (IHC) experiments, per-
formed separately at several medical facilities, revealed 
a serious loss in the ability to induce the expression of 
PSMB9/β1i in human U-LMS tissues in comparison with 
normal human myometrium tissues located in same 
tissue sections: normal myometrium; total 74 cases, 
uterine LMA; total 52 cases, Bizarre LMA; total 3 cases, 
U-LMS; total 58 cases. Of the 58 patients with U-LMS 
that we examined, 49 were negative for PSMB9/β1i ex-
pression, 4 were focally positive, and 3 were partially 
positive. Two patients with U-LMS were analyzed for 
the expression of PSMB9/β1i [12,13]. PSMB9/β1i levels 
were also evaluated in skeletal muscle and rectal metas-
tases from individual patients with U-LMS, where sur-
gical samples showed the presence of a mass measur-
ing 3 cm in maximum diameter in the lumbar quadrate 
muscle without a fibrous capsule. All lymph nodes were 
negative for human LMS metastases, and IHC analyses 
with U-LMS showed positivity for Ki-67 (clone MIB1) 
and negativity for PSMB9/β1i (Figure 1 and Table 1). The 
defective expression of PSMB9/β1i detected in primary 
human U-LMS was also observed in the metastatic LMS 
of the skeletal muscle and rectum, indicating that the 
metastatic lesions conserved this biological character-
istic of primary human U-LMS. In both western blotting 
and RT-PCR experiments, PSMB9/β1i was expressed in 
normal myometrium but not in human U-LMS, which 
was strongly supportive of the IHC findings. Further-
more, analysis of a human U-LMS cell line clarified the 
biological significance of PSMB9/β1i in malignant myo-
metrium transformation and cell cycle, thus implicating 
PSMB9/β1i as an anti-tumorigenic candidate [12,13]. 
Human U-LMS reportedly is a highly metastatic smooth 
muscle neoplasm for which CALPONIN h1 is suspected 
to have a biological role as a tumor suppressor. More-
over, several lines of evidence indicate that although 
CALPONIN h1 does not directly influence tumorigenesis, 
it clearly affects PSMB9/β1i-induced cellular morpho-
logical changes [14].
There is only one prospective Phase II study of aro-
matase inhibitors in human U-LMS with primary end-
point of Progression-Free Survival (PFS) at 12 weeks 
[15]. Whilst no objective responses were seen stable 
disease was recorded in 14 out of 27 patients and PFS 
at 12 weeks of 50%, and median duration of treat-
ment only 2.2 months. This therapeutic approach has 
the benefit of being relatively well tolerated, especially 
when compared to chemotherapy and is recommend-
ed in patients with more indolent disease patterns and 
lower burden of disease. The physiological significance 
of PSMB9/β1i as a tumour suppressor may lead to new 
therapeutic targets in human U-LMS.
Conclusions
Defective expression of PSMB9/β1i is likely to be one 
of the risk factors for the development of human uter-
ine neoplasm, as it is in the PSMB9/β1i deficient mouse. 
Thus, combination of PSMB9/β1i with other functional 
candidates is useful for a novel diagnostic biomarker for 
human U-LMS [16-19]. Additionally, gene therapy with 
PSMB9/β1i expression vectors may be a new treatment 
for human U-LMS that exhibit a defect in PSMB9/β1i ex-
pression. Because there is no effective therapy for un-
respectable human U-LMS, our results may bring us to 
specific molecular therapies to treat this disease.
Note
Experimental procedure
Immunohistochemistry (IHC) was performed using 
the avidin-biotin complex method previously described 
[19]. Briefly, one representative 5-µm tissue section 
was cut from a paraffin-embedded sample of the radi-
cal hysterectomy specimen from 58 patients with uter-
ine Leiomyosarcoma (LMS), 52 patients with Leiomyo-
ma (LMA), 3 patients with Bizarre LMA, 1 patient with 
Leiomyomatoid Angiomatous Neuroendocrine Tumour 
(LANT)-like tumour, normal myometrium total 74 cases. 
Table 1: Differential expressions of PSMB9/β1i and Ki-67/MIB1 in human uterine mesenchymal tumours and uterine LANT-like 
tumour.
Age
years n
PSMB9/β1i expression* Ki-67/MIB1 expression*
- -/+1 Focal+2 +++3 - -/+1 Focal+2 +++3
Normal 32-83 74 74 74
Leiomyoma
(Ordinally leiomyoma)
(Cellular leiomyoma)
(Tumour of uncertain 
malignant potentialy)
33-83 52
(30)
(10)
(12)
52 10 15 27
Bizarre Leiomyoma 44,49,55 3 3 3
Leiomyosarcoma 32-83 58 49 3 4 2 2 4 52
U.LANT-like tumour 45 1 1 1
*Staining score of PSMB9/β1i expression and Ki-67/MIB1 expression from results of IHC experiments; -/+1: Partially positive 
(5% to 10% of cells stained); Focal+2: Focal-positive (focal or sporadic staining with less than 5% of cells stained); +++3: Diffuse-
positive (homogenecus distribution with more than 90% of cells stained); -: Negative (no stained cells); U.LANT-like tumour: 
Uterine Leiomyomatoid Angiomatous Neuroendocrine Tumour-like tumour.
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Sections were deparaffinized and rehydrated in graded 
alcohols and then incubated with normal mouse serum 
for 20 min. Sections were incubated at room temper-
ature for 1 hour with anti-human PSMB9/β1i antibody 
and anti-Ki-67/MIB1 antibody (SIGMA-Aldrich Israel, 
Rehovot, Israel., dilution 1/100). Afterwards, sections 
were incubated with a biotinylated secondary antibody 
(Dako, Carpinteria, CA) and then exposed to a streptavi-
din complex (Dako). Complete reaction was revealed 
by 3,3’-diaminobenzidine, and the slide was counter-
stained with hematoxylin. Twenty one normal human 
myometrium sections from specimens were used as 
positive controls. Negative controls consisted of tissue 
sections also incubated with normal rabbit IgG instead 
of the primary antibody. These studies are registered, at 
Shinshu University in accordance with local guidelines 
(approval no. M192).
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